Further highlighting the pleiotropic role of CD44 in regulating different receptors, including Met, to promote cell plasticity and tumor growth [70,79], targeting CD44 with sTN58 led to a downregulation of the Met receptor. The gene discussed is MET; the disease is neoplasm.